Ubs Group Ag Lyra Therapeutics, Inc. Transaction History

Ubs Group Ag

$528 Billion
Q1 2025

A detailed history of Ubs Group Ag transactions in Lyra Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 434,226 shares of LYRA stock, worth $3.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

434,226

Previous 424,965 2.18%

Holding current value

$3.6 Million

Previous $89,000 37.08%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	BUY	$0.13 - $0.22 $1,203 - $2,037	9,261 Added 2.18%	434,226 $56,000
Q4 2024 Feb 14, 2025	BUY	$0.17 - $0.28 $68,008 - $112,014	400,050 Added 1605.66%	424,965 $89,000
Q3 2024 Nov 14, 2024	BUY	$0.24 - $0.34 $2,452 - $3,474	10,218 Added 69.52%	24,915 $6,000
Q2 2024 Aug 13, 2024	BUY	$0.26 - $6.25 $3,816 - $91,743	14,679 Added 81550.0%	14,697 $4,000
Q1 2024 May 13, 2024	SELL	$4.55 - $6.53 $21,758 - $31,226	-4,782 Reduced 99.63%	18 $0
Q4 2023 Feb 09, 2024	BUY	$2.82 - $5.24 $13,485 - $25,057	4,782 Added 26566.67%	4,800 $25,000
Q2 2023 Aug 11, 2023	SELL	$1.98 - $4.33 $1,653 - $3,615	-835 Reduced 97.89%	18 $0
Q1 2023 May 12, 2023	SELL	$1.95 - $3.09 $4,960 - $7,860	-2,544 Reduced 74.89%	853 $1,000
Q4 2022 Feb 08, 2023	BUY	$2.44 - $5.42 $739 - $1,642	303 Added 9.79%	3,397 $10,000
Q3 2022 Nov 10, 2022	BUY	$4.95 - $6.6 $5,306 - $7,075	1,072 Added 53.02%	3,094 $15,000
Q2 2022 Aug 10, 2022	BUY	$4.12 - $7.51 $8,256 - $15,050	2,004 Added 11133.33%	2,022 $11,000
Q1 2022 May 16, 2022	SELL	$3.5 - $5.36 $14,182 - $21,718	-4,052 Reduced 99.56%	18 $0
Q4 2021 Feb 14, 2022	BUY	$4.22 - $9.41 $17,099 - $38,129	4,052 Added 22511.11%	4,070 $18,000
Q3 2021 Nov 15, 2021	SELL	$6.06 - $9.43 $3,326 - $5,177	-549 Reduced 96.83%	18 $0
Q2 2021 Aug 13, 2021	SELL	$6.91 - $12.59 $15,112 - $27,534	-2,187 Reduced 79.41%	567 $5,000
Q1 2021 May 12, 2021	SELL	$10.38 - $15.61 $8,957 - $13,471	-863 Reduced 23.86%	2,754 $32,000
Q4 2020 Feb 11, 2021	BUY	$9.28 - $13.88 $25,696 - $38,433	2,769 Added 326.53%	3,617 $41,000
Q3 2020 Nov 12, 2020	SELL	$10.61 - $13.96 $9,209 - $12,117	-868 Reduced 50.58%	848 $9,000
Q2 2020 Jul 31, 2020	BUY	$10.91 - $18.56 $18,721 - $31,848	1,716 New	1,716 $19,000

Others Institutions Holding LYRA

# of Institutions

Shares Held

25M

Call Options Held

56.6K

Put Options Held

33.9K

View Full List

About Lyra Therapeutics, Inc.

Ticker LYRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,826,400
Market Cap $264M
Description
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained...

More about LYRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account